Sue Hill new Director of EMP

Dr Suzanne Hill began her appointment as Director of Essential Medicines and Health Products on 18 May, taking over from Kees De Joncheere. Dr Hill is a clinical pharmacologist and public health physician and has extensive experience working in several sectors, including in the government of her native Australia, internationally and in academia. More >

Two cutting-edge technologies for HIV detection in infants receive WHO prequalification

Two innovative technologies for early infant diagnosis of HIV newly prequalified by WHO will allow many more infants to be diagnosed quickly and placed on life-saving treatment. More >

Launch of new guidance to make children’s medicines safer and more effective

To address the gap in children’s medicines, the World Health Organization (WHO) and the International Pharmaceutical Federation (FIP) today release new guidelines for health care professionals prescribing or supplying medicines for children when no authorised product exists. The guidelines are available to all countries and professionals on the two organisations’ web sites. More >

WHO launches data integrity guidelines to protect patients all over the world
While developing a medicine and bringing it to market involves a multitude of actors and activities, a fundamental step is linked to the robustness and accuracy of the data submitted by manufacturers to national regulatory authorities. That data must be comprehensive, complete, accurate and true to assure the quality of studies supporting applications for medicines to be put on the market. WHO has developed a new guidance consolidating all normative principles into one document to help regulators identify insufficient or false data, improve the quality of medical products on global markets and, ultimately, improve health outcomes. More >

EMP at the World Health Assembly

Two resolutions related to access to health products were passed at the 69th World Health Assembly between 23-28 May. These resolutions aim to make quality health products more widely available and affordable and to reduce medicines and vaccines shortages in countries. In addition, the first ever list of Assistive Health Products was launched at a side event hosted by several governments. More >

Pioneering methadone programme gives hope to thousands in Dar es Salaam

In recent years, Dar es Salaam has seen an increase in illicit drug use, particularly heroin, as the large port city has become a pit stop for smugglers en route from Afghanistan to Europe and the rest of Africa. Widespread heroin use in an African country may seem unusual but what is even more surprising is the fact that two hospitals in Dar es Salaam now make methadone available as treatment for addiction. More >

Click to watch inspiring video

Surveying insulin availability and pricing: vital to treating diabetes

Collecting data on the availability and price of medicines is a crucial step in improving access to diabetes medicines like insulin, which is vital for the survival of people with Type 1 diabetes. The prevalence of diabetes has been steadily increasing for the past three decades and is growing most rapidly in low- and middle-income countries. The percentage of deaths attributable to high blood glucose or diabetes is almost 52% in low-income countries, compared with 23% in high-income countries. More >

WHO: Access to medicines
“If we can send people to the moon, surely we can get good medicines to all the people on earth!”

What does it take to become a good medicine? Understand the different implications and stakeholders in producing and releasing a medicine on the market. EMP works with countries to promote affordable access to quality, safe and effective medicines, vaccines, diagnostics and other medical devices. **Watch animation HERE >**

---

**Improving access to treatment for chronic diseases - Vietnam**

Dao Duy Tuoc, age 85, grew up in the village of Co Bi on the eastern outskirts of Hanoi, where he has lived his entire life. In the past, he and his neighbours were farmers and their village had more fields than homes. Now, everything has changed—"One thousand times over," he likes to say. He pays regular visits to the Co Bi Commune Health Centre to monitor hypertension. **More >**

---

**Resolution WHA69.23 on CEWG advances WHO’s work on R&D**

The 69th WHA adopted a strong resolution in the follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. In general, the resolution stresses the need for continuous efforts to promote more R&D into diseases that disproportionately affect developing countries and greater financial support to implement the global strategy and plan of action. **More >**

---

**GATE Initiative**

WHO’s first Priority Assistive Products List was launched at a side event of WHA69, prior to the EB139 agenda item on assistive technology. The Priority Assistive Products List is the first step of WHO’s GATE initiative towards improving global access to assistive products for everyone, everywhere. **More >**

---

**Coming soon**

08 - 09 July 2016 Copenhagen, Denmark Joint (PQT and MQA) meeting on regulatory guidance for assessment of multisource products **Medicines quality assurance >**
<table>
<thead>
<tr>
<th>Date</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 - 22 July 2016</td>
<td>WHO HQ, Geneva</td>
<td>R&amp;D Blueprint 2nd Technical workshop on platform technology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A research and development blueprint for action to prevent epidemics &gt;</td>
</tr>
<tr>
<td>25 - 29 July 2016</td>
<td>Ouagadougou, Burkina Faso</td>
<td>Adverse Events Following Immunization (AEFI) Surveillance Workshop (Regional)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Global Vaccine Safety &gt;</td>
</tr>
<tr>
<td>29 - 30 July 2016</td>
<td>Burkina Faso</td>
<td>Seasonal Malaria Chemoprevention Workshop</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Safety and Vigilance – Medicines &gt;</td>
</tr>
<tr>
<td>08 – 12 August 2016</td>
<td>Hyderabad, India</td>
<td>WHO advanced in-country workshop on good manufacturing practices regulatory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>inspection using the risk based approach</td>
</tr>
<tr>
<td>05 – 07 Sept 2016</td>
<td>Rabat, Morocco</td>
<td>Pharmacovigilance, ATC DDD and preventable adverse events</td>
</tr>
</tbody>
</table>

Visit EMP
http://who.int/medicines